BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis
Authors: J K L Gunn, C B Rosales, K E Center, A Nuñez, S J Gibson, C Christ, J E Ehiri
BMJ Open, 5 April 2016
—
Objective: To assess the effects of use of cannabis during pregnancy on maternal and fetal outcomes. Data sources: 7 electronic databases were searched from inception to 1 April 2014. Studies that investigated the effects of use of cannabis during pregnancy on maternal and fet…
The impact of ADHD persistence, recent cannabis use, and age of regular cannabis use onset on subcortical volume and cortical thickness in young adults.
Authors: Krista M. Lisdahl, Leanne Tamm, Jeffery N. Epstein, Terry Jernigan, Brooke S. G. Molina, et al
Drug and Alcohol Dependence, 1 April 2016
—
BACKGROUND: Both Attention Deficit Hyperactivity Disorder (ADHD) and chronic cannabis (CAN) use have been associated with brain structural abnormalities, although little is known about the effects of both in young adults. METHODS: Participants included: those with a childho…
Editorial: Lung macrophages high on cannabinoids: jamming PAMs and taming TAMs?
Authors: Jürg Gertsch
Journal of Leukocyte Biology, April 2016
—
Discussion of cannabinoid receptors and the ECS in macrophage activation.
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Authors: Orrin Devinsky, Eric Marsh, Daniel Friedman, Elizabeth Thiele, Linda Laux, et al
The Lancet Neurology, March 2016
—
BACKGROUND: Almost a third of patients with epilepsy have a treatment-resistant form, which is associated with severe morbidity and increased mortality. Cannabis-based treatments for epilepsy have generated much interest, but scientific data are scarce. We aimed to establish w…
In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma.
Authors: T. Fisher, H. Golan, G. Schiby, S. PriChen, R. Smoum, I. Moshe, N. Peshes-Yaloz, et al
Current Oncology, March 2016
—
BACKGROUND: Neuroblastoma (nbl) is one of the most common solid cancers in children. Prognosis in advanced nbl is still poor despite aggressive multimodality therapy. Furthermore, survivors experience severe long-term multi-organ sequelae. Hence, the identification of new ther…
Integrating cannabis into clinical cancer care.
Authors: D.I. Abrams
Current Oncology, March 2016
—
Cannabis species have been used as medicine for thousands of years; only since the 1940s has the plant not been widely available for medical use. However, an increasing number of jurisdictions are making it possible for patients to obtain the botanical for medicinal use. For t…
Use of cannabinoids in cancer care: palliative care.
Authors: S.K. Aggarwal
Current Oncology, March 2016
—
Integrating cim into oncologic palliative care promises to improve overall health-related quality of life, to provide further relief from distressing symptoms and spiritual suffering, and to bring hope to patients and families facing terminal illness. O’Shaughnessy offers the…
The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review.
Authors: Leos Landa, Alexandra Sulcova, P. Gbelec
Veterinarni Medicina, March 2016
—
Cannabinoids/medical marijuana and their possible therapeutic use have received increased attention in human medicine during the last years. This increased attention is also an issue for veterinarians because particularly companion animal owners now show an increased interest…
Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study
Authors: Assaf Shelef, Yoram Barak, Uri Berger, Diana Paleacu, Shelly Tadger, Igor Plopsky, Yehuda Baruch
Journal of Alzheimer’s Disease, 27 February 2016
—
BACKGROUND: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer’s disease (AD). OBJECTIVE: To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia…
Cannabinoids to treat spinal cord injury.
Authors: Angel Arevalo-Martin, Eduardo Molina-Holgado, Daniel Garcia-Ovejero
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 4 January 2016
—
Spinal cord injury (SCI) is a devastating condition for which there is no standard treatment beyond rehabilitation strategies. In this review, we discuss the current knowledge on the use of cannabinoids to treat this condition. The endocannabinoid system is expressed in the in…
Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed.
Authors: Margaret Haney, A. Eden Evins
Neuropsychopharmacology, January 2016
—
There have been extensive policy shifts in the legality of recreational and therapeutic use of cannabis in the United States, as well as a steady increase in the number of people using the drug on a regular basis. Given these rapid societal changes, defining what is known scie…
Preferential epithelial expression of type-1 cannabinoid receptor (CB1R) in the developing canine embryo.
Authors: Andrea Pirone, Carla Lenzi, Alessandra Coli, Elisabetta Giannessi, Maria Rita Stornelli, Vincenzo Miragliotta
SpringerPlus, 22 December 2015
—
The use of cannabinoid receptor agonists is gaining a strong interest both in human and veterinary medicine. The potential use of cannabimimetic compounds in companion animals was reviewed in 2007 for their role in tissue inflammation and pain. A better knowledge of type-1 can…